Navigation Links
NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
Date:2/29/2008

IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals Inc. (OTC Bulletin Board: NURX) today announced it has retained Russo Partners LLC for the provision of investor relations and corporate communications counsel.

The healthcare communications firm will implement a comprehensive program that consists of investor targeting, the scheduling of presentations at industry conferences, media relations and other corporate visibility initiatives. Russo Partners will collaborate with OTC Communications, a division of Rx Communications Group LLC, on the implementation of some program tactics.

"We are in a unique position with a clinical-stage pipeline and large portfolio of retinoid and rexinoid compounds that were developed over a number of years by world-class researchers who have joined the NuRx scientific team," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to initiate three to four clinical trials this year. Therefore, the need to support the associated news flow prompted us to select Russo Partners to develop and lead our communications efforts with Wall Street and the biotech/pharmaceuticals community. The firm has the healthcare industry expertise, senior-level talent and investor and media relationships that were critical to our selection of a communications partner."

Russo Partners LLC, formerly Noonan Russo, provides strategic communications services to emerging healthcare - biotech, medical device, diagnostics and healthcare services - companies worldwide. Headquartered in New York City, the firm has a West Coast office in San Diego and an affiliated office in London. For more information, visit http://www.russopartnersllc.com.

NuRx Pharmaceuticals Inc. is an emerging biotech company focused on the development of retinoid and rexinoid compounds with application in oncology (treatment, prevention and adjunctive supportive therapy), the treatment of diabetes, the regulation of lipid metabolism and bone metabolism and repair. The company's lead compounds are (1) NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha subtype- specific agonist for the treatment of acute leukemia; and (3) NRX4310, a function selective receptor modulator for the treatment and prevention of chemotherapy-induced neutropenia. Located in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

CONTACTS: Media

David Schull

(212) 845-4271

david.schull@russopartnersllc.com

Investors

Rhonda Chiger

(917) 322-2569

rchiger@rxir.com


'/>"/>
SOURCE NuRx Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
2. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
3. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
10. JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)
11. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... Brian Lula, president of Physik Instrumente USA, have been selected as this year’s recipients ... . , The two have been invited along with other honorees to accept their ...
(Date:6/22/2017)... ... 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the ... to manage the new site. , Tim has 25 years of pharmaceutical experience, ... role as the Director of Manufacturing and Supplier Quality Assessment. This group ...
(Date:6/22/2017)... ... June 22, 2017 , ... For ... has produced a Spotlight series on “Cell Therapy Regulation” for ... by leading experts on the unique regulatory challenges of stem cell medical research. ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce that ... to be appropriate as a screening test at dairies and farms for raw commingled ... and the Charm EZ Lite system. These systems are a combination incubator and reader ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):